Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291213 · ClinicalTrials.gov registry record · Phase 3
Levetiracetam Treatment of Tardive Dyskinesia
A Phase 3 study of Tardive Dyskinesia, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00291213 is a Phase 3 study of Tardive Dyskinesia that has completed, run by Yale University. The registered enrollment target is 50 participants, below the 139-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00291213, a Phase 3 study of Tardive Dyskinesia, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
Conditions Studied
Interventions
- DRUG placebo
- DRUG levetiracetam
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291213
The ClinicalTrials.gov registry entry for NCT00291213 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (64% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tardive Dyskinesia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00291213 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00291213 about?
NCT00291213 is a clinical study titled "Levetiracetam Treatment of Tardive Dyskinesia". This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
What is the current status of trial NCT00291213?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants.
What conditions does trial NCT00291213 study?
This clinical trial studies the following conditions: Tardive Dyskinesia.
What interventions are being tested in trial NCT00291213?
The interventions under investigation include: placebo (DRUG), levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00291213?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00291213 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tardive Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Involuntary Movements in Tardive Dyskinesia
COMPLETED · Phase 3
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
RECRUITING · NA
-
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.